Balyasny Asset Management’s Revance Therapeutics, Inc. RVNC Stock Holding History

Balyasny Asset Management’s Portfolio RVNC Stock Details RVNC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,500	Closed	-$71.4K	–	3412
2024 Q4	$71.4K	Sell	23,500 -100,000	-81%	-$436K	﹤0.01%	2625
2024 Q3	$641K	Buy	+123,500	New	+$614K	﹤0.01%	2162
2015 Q4	–	Sell	-100,000	Closed	-$2.98M	–	1491
2015 Q3	$2.98M	Buy	+100,000	New	+$3.04M	0.02%	612

Other funds holding RVNC

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Balyasny Asset Management's RVNC Position: Q4 2024 in Review

Balyasny Asset Management sold out of Revance Therapeutics, Inc. (RVNC) in Q4 2024, closing a stake of 96,154 shares — an estimated $419K sold.

Balyasny Asset Management first reported a position in RVNC in Q1 2015 and held it in 8 quarters. The position peaked at $5.39M in Q3 2023. 173 funds tracked by Wall St. Rank hold RVNC as of Q4 2024.

Balyasny Asset Management reported no remaining Revance Therapeutics, Inc. position as of Q4 2024 after selling out during the quarter.
Balyasny Asset Management sold 96,154 Revance Therapeutics, Inc. shares in Q4 2024, an estimated $419K.
Balyasny Asset Management first reported a position in Revance Therapeutics, Inc. in Q1 2015 and held it in 8 quarters.
Balyasny Asset Management's Revance Therapeutics, Inc. position peaked at $5.39M in Q3 2023.
173 funds tracked by Wall St. Rank held Revance Therapeutics, Inc. as of Q4 2024.

Based on Balyasny Asset Management's 13F filing for Q4 2024, filed 14 Feb 2025.